Download PDF

1. Company Snapshot

1.a. Company Description

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for pharma and healthcare.Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines.The company was founded in 1949 and is headquartered in Piombino Dese, Italy.


Stevanato Group S.p.A. operates as a subsidiary of Stevanato Holding S.R.L.

Show Full description

1.b. Last Insights on STVN

The recent 3-month performance of Stevanato Group S.p.A. has been negatively impacted by a decline in investor sentiment, as evidenced by the stock reaching a new 52-week low on February 1, 2026. The stock traded as low as €15.40, with a volume of 1057900 shares trading hands. This decline in investor sentiment may be attributed to a lack of positive catalysts, such as new product launches or partnerships, which have been a key driver of the company's growth in the past. Additionally, the company's recent collaboration with LTS Device Technologies and Datwyler may not have been enough to offset the negative sentiment. The lack of analyst upgrades and downgrades in recent months also suggests that investors are becoming increasingly bearish on the stock.

1.c. Company Highlights

2. Stevanato Group's Q3 Earnings: A Strong Performance Driven by High-Value Solutions

Stevanato Group reported a solid third-quarter performance, driven by revenue growth, a record mix of high-value solutions, and continued margin expansion. Revenue increased by 9% year-over-year to $303.2 million, with the BDS segment growing by 14%, primarily fueled by demand for high-value solutions such as Nexa syringes and EZ-fill vials. High-value solutions grew 47% and represented 49% of total company revenue. The company's gross profit margin increased to 29.2%, driven by a favorable mix of high-value solutions and financial improvements at its Latin and Fishers facilities. Operating profit margin increased to 17.4%, and adjusted operating profit margin rose 220 basis points to 18.5%. Net profit totaled $36.1 million, with diluted EPS of $0.13, and adjusted diluted EPS increased 17% to $0.14, slightly below the actual EPS of $0.16.

Publication Date: Nov -16

📋 Highlights
  • Revenue Growth: Total revenue rose 9% YoY to $303.2 million, with BDS segment up 14% and high-value solutions contributing 49% of revenue (47% growth).
  • Margin Expansion: Gross profit margin hit 29.2%, operating margin reached 17.4%, and adjusted operating margin rose 220 bps to 18.5%.
  • 2025 Guidance: Revenue projected at $1.16–$1.19 billion, adjusted EBITDA $288.5–$301.8 million, and adjusted diluted EPS $0.50–$0.54.
  • High-Value Solutions Dominance: Expected to account for 43–44% of revenue in 2025, driven by Nexa syringes, Alba cartridges, and biosimilar opportunities.
  • Strategic Investments: $100M+ allocated to high-speed syringe lines in Fishers and Latina, targeting full capacity by 2028, plus US onshoring opportunities.

Segment Performance and Guidance

The Engineering segment experienced a slowdown due to delays in order conversion, but the pipeline with clients remains healthy. The company won a significant biosimilar opportunity for GLP-1s, which will contribute to growth. Stevanato reiterated its fiscal 2025 guidance, expecting revenue in the range of $1.16 billion to $1.19 billion, adjusted EBITDA between $288.5 million and $301.8 million, and adjusted diluted EPS between $0.50 and $0.54.

Growth Drivers and Strategy

Biosimilars are expected to play a crucial role in the company's growth, with a strategy to be present in all injectable products, both originators and biosimilars. The company has a history of being involved with originators from the beginning and is now actively working with biosimilars. Stevanato's investments are focused on high-value products, which is expected to drive growth. The company's goal is to serve clients with full system solutions for high-value products.

Valuation and Outlook

With a P/E Ratio of 37.52 and an EV/EBITDA of 20.16, the market is pricing in a certain level of growth for Stevanato Group. Analysts estimate next year's revenue growth at 9.6%. The company's strong performance, healthy pipeline, and clear strategic focus position it well to drive growth and deliver lasting value for customers, employees, and shareholders. The expected growth in biologics, particularly in Nexa syringes and Alba cartridges, will likely contribute to the company's continued growth.

3. NewsRoom

Card image cap

Financial Review: Kiora Pharmaceuticals (NASDAQ:KPRX) & Stevanato Group (NYSE:STVN)

Feb -09

Source: defenseworld.net

Card image cap

Stevanato Group (NYSE:STVN) Reaches New 52-Week Low – Time to Sell?

Feb -01

Source: defenseworld.net

Card image cap

Alger Small Cap Focus Fund Q4 2025 Portfolio Update

Jan -29

Source: seekingalpha.com

Card image cap

STVN or MDGL: Which Is the Better Value Stock Right Now?

Jan -26

Source: zacks.com

Card image cap

Stevanato Group S.p.A. (NYSE:STVN) Given Consensus Rating of “Moderate Buy” by Brokerages

Jan -24

Source: defenseworld.net

Card image cap

Datwyler, LTS Device Technologies, and Stevanato Group Collaborate to Expand Self-Delivery Options for Large-Volume Drugs

Jan -16

Source: prnewswire.com

Card image cap

Stevanato: Structural Growth Intact, Buy Confirmed

Jan -03

Source: seekingalpha.com

Card image cap

SDZNY vs. STVN: Which Stock Is the Better Value Option?

Dec -19

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (12.69%)

6. Segments

Biopharmaceutical and Diagnostic Solutions

Expected Growth: 12.5%

Stevanato Group's Biopharmaceutical and Diagnostic Solutions segment growth is driven by increasing demand for high-quality pharmaceutical containers, rising adoption of biologics and vaccines, and growing need for diagnostic solutions. Additionally, the company's strategic investments in R&D, expansion into emerging markets, and partnerships with leading pharmaceutical companies contribute to its 12.5% growth.

Engineering

Expected Growth: 13.5%

Stevanato Group's 13.5% growth in Engineering is driven by increasing demand for high-value pharmaceutical containers and devices, expansion into emerging markets, and strategic partnerships. The company's innovative products, such as its EZ-fill vials and cartridges, are gaining traction, while its investments in digitalization and automation are improving operational efficiency.

7. Detailed Products

Pharmaceutical Glass Containers

Stevanato Group offers a wide range of pharmaceutical glass containers, including vials, cartridges, and syringes, designed for pharmaceutical and biotechnological applications.

Diagnostic Glass Tubes

Stevanato Group provides diagnostic glass tubes for blood collection, serum separation, and other laboratory applications.

Syringe Systems

Stevanato Group designs and manufactures syringe systems, including staked-needle syringes, luer-lock syringes, and other customized solutions.

Cartridge Systems

Stevanato Group offers cartridge systems for pharmaceutical and biotechnological applications, including dual-chamber cartridges and other customized solutions.

Vial Containment Solutions

Stevanato Group provides vial containment solutions, including vial adapters, vial stoppers, and other customized solutions.

Inspection and Packaging Machines

Stevanato Group designs and manufactures inspection and packaging machines for pharmaceutical and biotechnological applications.

Visual Inspection Systems

Stevanato Group offers visual inspection systems for pharmaceutical and biotechnological applications, including machine vision and artificial intelligence-based solutions.

8. Stevanato Group S.p.A.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Stevanato Group S.p.A. is medium due to the presence of alternative packaging solutions, but the company's focus on innovation and sustainability helps to mitigate this threat.

Bargaining Power Of Customers

The bargaining power of customers is low for Stevanato Group S.p.A. due to the company's strong relationships with its customers and its ability to provide customized solutions.

Bargaining Power Of Suppliers

The bargaining power of suppliers is medium for Stevanato Group S.p.A. due to the company's dependence on a few key suppliers, but the company's strong relationships with its suppliers help to mitigate this risk.

Threat Of New Entrants

The threat of new entrants is low for Stevanato Group S.p.A. due to the high barriers to entry in the pharmaceutical packaging industry, including the need for significant investment in research and development.

Intensity Of Rivalry

The intensity of rivalry is high for Stevanato Group S.p.A. due to the competitive nature of the pharmaceutical packaging industry, but the company's focus on innovation and sustainability helps to differentiate it from its competitors.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 25.40%
Debt Cost 3.95%
Equity Weight 74.60%
Equity Cost 7.71%
WACC 6.75%
Leverage 34.05%

11. Quality Control: Stevanato Group S.p.A. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Tecan

A-Score: 3.9/10

Value: 4.9

Growth: 4.1

Quality: 6.1

Yield: 2.5

Momentum: 1.0

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Carl Zeiss Meditec

A-Score: 3.4/10

Value: 4.0

Growth: 5.1

Quality: 5.7

Yield: 1.9

Momentum: 1.5

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Stevanato

A-Score: 3.2/10

Value: 1.5

Growth: 5.4

Quality: 5.5

Yield: 0.0

Momentum: 6.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Sartorius

A-Score: 2.8/10

Value: 0.6

Growth: 5.3

Quality: 4.0

Yield: 0.0

Momentum: 4.0

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Gerresheimer

A-Score: 2.6/10

Value: 7.2

Growth: 4.4

Quality: 1.9

Yield: 1.2

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
NovoCure

A-Score: 2.4/10

Value: 7.2

Growth: 3.0

Quality: 3.6

Yield: 0.0

Momentum: 0.0

Volatility: 0.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

16.05$

Current Price

16.05$

Potential

-0.00%

Expected Cash-Flows